What is the purpose of Palivizumab (Synagis)?

Palivizumab, marketed as Synagis, is specifically designed for the prophylaxis of respiratory syncytial virus (RSV) infection in high-risk infants and children. RSV is a significant cause of respiratory illness in young children, particularly those born prematurely or with certain medical conditions that make them more susceptible. By administering Palivizumab, healthcare providers aim to reduce the risk of severe RSV illness that could lead to hospitalization.

This monoclonal antibody works by binding to the RSV, preventing the virus from entering and replicating in cells, thereby providing a preventive measure rather than a treatment for an active infection. The focus of Palivizumab on RSV prevention highlights its specialized use in a vulnerable population, distinguishing it from medications used for conditions like asthma or bacterial infections.